🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

First runner up in the outstanding group of new YIs was the incredible Chetan Vakkalagadda, MD from Northwestern Medicine presenting his work on the phase 2 trial of osimertinib with it without olaparib in stage 4 EGFRm NSCLC with HRD. 🙌🎉 #EGFRSummit22 #lcam #lcsm EGFR Resisters

(1/3) Honored by the opportunity to share my #NSCLC cancer journey & my experiences with shared decision making. 📢“Chasing Milestones” was just published as an Journal of Clinical Oncology Art of Oncology Article. 🙏 Please read: Chasing Milestones ascopubs.org/doi/pdf/10.120… #JCO #ARTOFONCOLOGY

Great reunion of fellows from #vailworkshop #MCCR22 at ASCO GI! #GI23 Chetan Vakkalagadda, MD Michael Iglesia, MD, PhD Madhu Eluri, MD Linda Wu, MD

A Purdy unbelievable run. The San Francisco 49ers are headed to the NFC Championship! #NFLPlayoffs #DALvsSF

🎯Targeted therapy is not so targeted if it doesn’t target all patients!! In this JAMA Network Open paper, 66% of Medicaid patients with EGFR & ALK mut #NSCLC received targeted therapies across all states. #LCSM #HOFellows Hem-Onc Fellows Network EGFR Resisters @ALKLungCancer LUNGevity Foundation

I did not expect this piece to resonate with so many people. This is dedicated to all the clinicians in the trenches. thelancet.com/journals/lanha…

Lung Cancer Sessions that you should not miss #ASCO23 #LCSM The Cancer News OncoAlert Oncology Brothers

The future of thoracic oncology OncLive.com Fellows Forum at #ASCO23 MJH Life Sciences® ASCO

🎉 Join us for #EGFRSummit, in collab w/ @egfrresisters & @CEC_onc! Improve your #Research skills, evaluate peers' work & 🚀your career as a #LungCancer researcher! Submit Abstracts by Aug 18➡️ce.ceconcepts.com/EGFR23 Jill Feldman Ivy Elkins Zosia Piotrowska #LCSM #EGFR #NSCLC

We are so proud of our graduating fellows! Congratulations to Dr. Madelyn Burkart, Dr. Jacob Choi, Dr. Sara Small SaraSmallMD, Dr. Frederique St-Pierre Frédérique St-Pierre, and Dr. Chetan Vakkalagadda Chetan Vakkalagadda, MD. We will miss each of you and can't wait to see your careers blossom!

FDA approves first perioperative immunotherapy regimen for resectable NSCLC. Based on KEYNOTE 671, #neoadjuvant pembrolizumab + chemotherapy followed by one year of adjuvant pembrolizumab now FDA approved for pts with resectable (T≥4 cm or N+) NSCLC. businesswire.com/news/home/2023…

Lung cancer is hard to spot. At OHSU Knight Cancer Institute, we know catching it early makes a big difference. #LungCancer can be treated and cured – if you spot it early. Screening is the key. It’s fast and easy. Make a difference for yourself. You’ll breathe easier: spr.ly/6017uto8f

Thank you Dr. Liu for highlighting our work! Unexpected resistance mutations can develop in patients with lung cancer on targeted therapies, making it important we do molecular testing at progression. #lcsm Jyoti D Patel Northwestern Hematology/Oncology Fellowship OHSU Knight Cancer Institute

Some reflections on implementation of liquid biopsy for cancer care JCO Precision Oncology. Authors note that new assays can decrease or deepen disparities and we are at a fork in the road. Need to simplify ordering and interpretation and address reimbursement. ascopubs.org/doi/abs/10.120…

One more day at #WCLC24 for IASLC JTO & JTO CRR reviewer workshop. Learned tremendously from faculty on how to review manuscripts together with friends! Ivy Riano, M.D. Chetan Vakkalagadda, MD Rajat Thawani Julie Wu So Yeon Kim

Please read our latest paper published in Annals of Oncology on the choice of platinum in NSCLC. This was published as a letter to the editor. annalsofoncology.org/article/S0923-…

Excellent opportunity to learn and network! And get an extra day at #WCLC25 IASLC Chetan Vakkalagadda, MD So Yeon Kim Lei Deng, MD (He/Him) Ivy Riano, M.D.

Presented at #ASCO25: A 3-year structured exercise program after adjuvant chemotherapy for colon cancer improved disease-free and overall survival, physical functioning, and fitness, as compared with health education alone. Full CHALLENGE phase 3 trial results: